|
 |
|
EDRI Federal Project Inventory:
60954-03 Case-Control Study of DMPA and Breast Cancer
- Sponsor Organization: NIH/NCI
- Project Title: 60954-03 CASE-CONTROL STUDY OF DMPA AND BREAST CANCER
- Project Focus: HUMAN HEALTH EFFECTS
- Description: The injectable contraceptive progestagen, depot medroxyprogesterone
acetate (DMPA), has been used worldwide byover 11 million women.
Concerns exist about breast cancer risk, particularly following long
term use. Yet the fewepidemiological studies carried out to date have
not had the data to assess risk immediately following long-term use,
orafter a delay. It is also possible that in the short term DMPA may
increase risk, and in the long term reduce it. Hypothesis. The study
will assess whether DMPA use for 5= years increases (or decreases)
breast cancer risk overall,or after a latent interval. It will also
assess risk according to duration of exposure, and in subgroups (e.g.,
exposure inadolescence; risk according to age at occurrence of breast
cancer). Methods. A hospital-based case-control study willbe carried
out in the Western Cape of South Africa. 382 African (i.e., black)
and Colored (i.e., mixed ancestry) casesbelow age 55 will be compared
with 1,528 controls frequency-matched for age, ethnic group and
hospital. Whitewomen will be excluded because DMPA use among them is
uncommon. Among potential controls preliminaryinvestigations have
established that over 30ave ever used DMPA; well over 10ave been
exposed for 5+ years. These are the highest documented exposure rates
in the world. On the conservative assumption of 10 4.540000e+02xposure for
5+years, power will be at least 80to document an increased (or
- References:
- Category: MEASUREMENTS
- Subcategory: EXPOSURE AND RISK MODELS
- Keywords for Experimental System/Species: HUMAN, FIELD STUDY
- Keywords for Experimental Endpoints: EXPOSURE MONITORING, EPIDEMIOLOGY, CARCINOGENESIS
- Chemical Agents: PROGESTAGEN, DEPOT MEDROXYPROGESTERONE ACETATE (DMPA)
- Performing Institution: BOSTON UNIVERSITY
- Contact: CONTACT PERSON: ELAINE C. LEE; BUILDING 31; 11A21; NATIONAL CANCER
INSTITUTE, NIH,BETHESDA, MD 20892-2590; 301 496-5515;
LEEE@OD.NCI.NIH.GOV
|
|
